Full employer posting
Malignant Hematology & Cellular Therapy Subspecialist Opportunity Deaconess Cancer Center – Newburgh/Evansville, Indiana Position Overview New Comprehensive Cancer Center coming in 2028! This future destination cancer center will bring together cutting-edge technology, leading specialists and compassionate, coordinated care, all in one place so patients across the Tri-State can receive world-class cancer care close to home.
To learn more about the center, please visit www.deaconess.com/cancercenter The Deaconess Cancer Center is seeking a board-certified/board-eligible Hematologist-Oncologist with fellowship training or subspecialty interest in malignant hematology and/or cellular therapy to lead and grow care for patients with leukemia, lymphoma, myeloma, and other hematologic malignancies. This is a unique opportunity to join a highly collaborative, disease-site-focused oncology program with strong institutional support for sub-specialization, program development, and clinical innovation in malignant hematology and cellular therapy.
Program Highlights Disease-Site Model: Join established and growing programs across 8+ disease sites with dedicated physician leadership. Subspecialty Growth: Strategic investment in Malignant Hematology and Cellular Therapy as a dedicated disease-site program. Multidisciplinary Excellence: Join a collegial, multidisciplinary team of providers from various specialties.
Our group thrives on collaboration, mentorship and shared decision-making. Dedicated Tumor Board: Hematologic malignancies tumor board, part of a specialized tumor board structure that also includes GI, urologic, head and neck, cutaneous, gynecologic, thoracic, breast and neurologic malignancies. Advanced Infrastructure: Epic EMR with Beacon oncology module, Abridge AI documentation and ordering assistance.
Robust Support Team: Experienced APPs, oncology pharmacists, nurse navigators, dietitians, social workers, palliative care, and rehab specialists. Clinical Practice Flexible 4- or 5-day workweek 1:8 call schedule Opportunity to develop a focused malignant hematology and cellular therapy practice while maintaining optional general oncology exposure. Strong referral base across a large regional footprint Compensation & Benefits $700,000 guaranteed base salary (Year 1) with average earnings over $1M Productivity incentives + APP supervision compensation + Quality Bonus Up to $100,000 sign-on bonus plus training stipends available for current Fellows Comprehensive benefits package, including: 5 weeks PTO + 6 holidays CME: 5 days + $3,500 annually 401(k) + 457(b) retirement plans Full health, dental, vision, and life insurance Paid licensing, DEA, and board fees Up to $15,000 relocation assistance Technology stipend Ideal Candidate Fellowship training and/or strong clinical interest in malignant hematology and/or cellular therapy Commitment to multidisciplinary, patient-centered cancer care Interest in program development and leadership in malignant hematology and cellular therapy Interest in hematologic malignancy clinical trials – strongly encouraged Collaborative mindset within a growing oncology service line Why Evansville & Newburgh, Indiana Located along the Ohio River, Evansville offers a regional hub for healthcare, culture, and education, while nearby Newburgh provides a charming, historic riverfront community.
Together, they offer: Affordable cost of living with excellent schools Vibrant arts, dining, and outdoor recreation Easy access to Indianapolis, Nashville, Louisville and St. Louis Contact Information Michelle Dexter, Physician Recruiter 📞 812-450-7263 📧 Michelle. Dexter@deaconess.com Apply Today Submit your CV directly to Michelle Dexter and explore how you can help shape the future of malignant hematology and cellular therapy care at Deaconess.
About the role
This is a unique opportunity to join a highly collaborative, disease-site-focused oncology program with strong institutional support for sub-specialization, program development, and clinical innovation in malignant hematology and cellular therapy. Strategic investment in Malignant Hematology and Cellular Therapy as a dedicated disease-site program.
